Isomorphic Labs Raises $5B to Take AI-Designed Drugs Into Clinical Trials
Isomorphic Labs, which spun out of Google DeepMind, raised $5B in a Series C round to move its AI-designed drugs into clinical trials. Greenoaks and Sequoia Capital led the round, Andreessen Horowitz joined as a new investor, and existing backers invested again. The company reports positive preclinical results in oncology and immunology and works with Eli Lilly, Novartis, and Johnson & Johnson. The takeaway: the market is willing to pay billions for an AI platform that can reach real medicines.
AI-processed from TechCrunch; edited by Hamidun News
Most AI startups sell subscriptions or APIs. Isomorphic Labs is selling something riskier: the chance that neural networks can help create a drug that reaches patients. On November 17, 2026, the company announced a $5B Series C round. It is one of the largest AI-driven biotech rounds to date, and its significance goes beyond the amount. The open question is whether such investments will pay off once these drugs have to be tested in people.
Who Invested and How Much
Isomorphic Labs spun out of Google DeepMind in 2021. Greenoaks and Sequoia Capital co-led the round. Andreessen Horowitz came in as a new investor. All previous backers also invested again, including Alphabet's venture arms GV and Capital G, Thrive Capital, MGX, Temasek, and the British Sovereign AI Fund.
For a founder and investor, this is a telling detail. When existing backers add money rather than just watching new investors arrive, it usually signals confidence in momentum. The new round follows the $2.1B Series B, which closed in May, almost immediately. In six months, the company has raised more than $7B.
The company did not disclose its valuation. Bloomberg reported earlier this month that Isomorphic sought to raise funds at a valuation of around $50B. The company has not confirmed this, so the figure should be treated as a rumor.
What the Company Is Building
Isomorphic is building a "drug design engine." Put simply, it is a set of simulation models, each specializing in a different area of chemistry, for example how a molecule might behave next to a target protein. Traditional drug development resembles finding the right key for a lock by testing thousands of candidates in the lab. Isomorphic's approach is to run the variants in simulation first and send only the most promising ones to the lab.
The foundation is AlphaFold, the DeepMind model that predicts a protein's three-dimensional structure from its genetic sequence alone. Demis Hassabis and John Jumper received the Nobel Prize in Chemistry for this work. According to TechCrunch, Hassabis is Isomorphic's founder and CEO, and he moved to the role of chair at DeepMind to focus on drug development. The Series C is the company's first round since that decision.
The company reports "positive preclinical results" in oncology and immunology. This means the candidates showed encouraging data in laboratory and animal models, but not in humans. The announcement does not give details: which specific molecules, how effective they are, or how they compare with existing treatments.
What the Money Is For, and the Catch
The new funds will go toward developing the engine and expanding into other types of drugs. The main goal is stated plainly: bring candidates into clinical trials. This is where the path gets most expensive. Clinical phases take years and cost enormous sums, and a significant share of drugs fail precisely at this stage, regardless of how they were designed.
So the honest conclusion is this: AI may speed up and cheapen the early stage, but there is still no public evidence that it improves the odds of success in the clinic. Deals with Eli Lilly, Novartis, and Johnson & Johnson show that pharmaceutical giants are willing to work with the platform. But a preclinical partnership and an approved drug are different things.
For developers and founders, the story offers several practical lessons:
- Investors are shifting from paying for "AI demos" to paying for AI platforms tied to a physical result: a drug, a material, a chip.
- Scientific breakthroughs from labs like DeepMind are becoming standalone companies with their own billion-dollar budgets.
- The measure of success in these projects is not model accuracy but whether a candidate reaches a patient. That can only be verified years from now.
If Isomorphic's clinical data turns out to be strong, it will be the most compelling argument yet for AI in biotech. If not, rounds of this size will have to be justified all over again.
- Nov 21, 2026Anthropic Paid $3.4 Billion for 1.7 GW of Gas Generators
- Nov 21, 2026Gemini 4 Hydrogen: Google's Junior Model Beats the Senior Argon and Runs 2.5x Faster Than Flash
- Nov 21, 2026OpenAI Names 4 Reasons GPT-6 Astra Hides Its Reasoning from Monitors
- Nov 21, 2026Alibaba's Wan 3.0 Tops the Video Leaderboard at 1175 Elo, $0.20 per Second
Key Questions Answered
Who Invested and How Much?
Isomorphic Labs spun out of Google DeepMind in 2021. Greenoaks and Sequoia Capital co-led the round. Andreessen Horowitz came in as a new investor. All previous backers also invested again, including Alphabet's venture arms GV and Capital G, Thrive Capital, MGX, Temasek, and the British Sovereign AI Fund. For a founder and investor, this is a telling detail. When existing backers add money rather than just watching new investors arrive, it usually signals confidence in momentum.
What the Company Is Building?
Isomorphic is building a "drug design engine." Put simply, it is a set of simulation models, each specializing in a different area of chemistry, for example how a molecule might behave next to a target protein. Traditional drug development resembles finding the right key for a lock by testing thousands of candidates in the lab. Isomorphic's approach is to run the variants in simulation first and send only the most promising ones to the lab.
What the Money Is For, and the Catch?
The new funds will go toward developing the engine and expanding into other types of drugs. The main goal is stated plainly: bring candidates into clinical trials. This is where the path gets most expensive. Clinical phases take years and cost enormous sums, and a significant share of drugs fail precisely at this stage, regardless of how they were designed.
Ship AI Faster with Founders, Engineers & Weekly Architecture Reviews
Inside Vibe Club (hamidun.com/club) — weekly live masterminds with Zhemal Khamidun, Tech Radar, full LMS access, and 370+ production Claude Code skills.
The AI world, distilled — once a week
Seven stories that actually mattered, hand-picked. No noise, no reposts, no press releases.
Done! Check your inbox for a confirmation.